Literature DB >> 30822494

The value of Continuous Glucose Monitoring and Self-Monitoring of Blood Glucose in patients with Gestational Diabetes Mellitus during Ramadan fasting.

Bachar Afandi1, Mohamed Hassanein2, Sana Roubi3, Nico Nagelkerke4.   

Abstract

INTRODUCTION: In order to achieve the recommended glycemic control, women with Gestational Diabetes Mellitus (GDM) are instructed to self-monitor blood glucose (SMBG) regularly. The purpose of this study was to evaluate glucose readings provided by Continuous Glucose Monitoring (CGM) and SMBG in GDM patients during Ramadan fasting.
METHODS: This is a prospective observational study that recruited GDM patients treated with diet ± metformin were enrolled. They agreed to wear the iPro®2 ProfessionalCGM device and to do SMBG by glucose reading meters, during fasting and after meals. We evaluated the rates of hypoglycemia and hyperglycemia in each approach. The frequency and timing of SMBG was investigated.
RESULTS: Twenty-five patients were recruited. A total of 36,628 readings by CGM device and 408 readings using glucose meters and were captured. Average glucose level was 103 ± 8 mg/dl (5.7 ± 0.4 mmol/l) and 113 ± 14 mg/d (6.28 ± 0.8 mmol/L) on CGM and glucose meters respectively. The rate of hyperglycemia was 5.65% and 14.2% and hypoglycemia was 4.35% and 1.5% using CGM and glucose meters respectively. While all hypoglycemic episodes occurred between 16:00-19:00 in both approaches, only 38 readings (9%) of SMBG readings were done in that time frame.
CONCLUSION: Although the frequency of SMBG using glucose meters for women with GDM and fasting Ramadan was acceptable, the timing was not. CGM detected more hypoglycemia and less hyperglycemia than SMBG. Relying on Intermittent SMBG in the management of GDM patients during Ramadan fasting might be misleading.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Continuous Glucose Monitoring; Fasting; Gestational Diabetes Mellitus; Hyperglycemia; Hypoglycemia; Ramadan; Self-Monitoring of Blood Glucose

Mesh:

Substances:

Year:  2019        PMID: 30822494     DOI: 10.1016/j.diabres.2019.01.036

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

Review 1.  Ramadan Fasting and Maternal and Fetal Outcomes in Pregnant Women with Diabetes Mellitus: Literature Review.

Authors:  Shejil Kumar; Terrence Diamond
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

2.  Largest Amplitude of Glycemic Excursion Calculating from Self-Monitoring Blood Glucose Predicted the Episodes of Nocturnal Asymptomatic Hypoglycemia Detecting by Continuous Glucose Monitoring in Outpatients with Type 2 Diabetes.

Authors:  Shoubi Wang; Zhenhua Tan; Ting Wu; Qingbao Shen; Peiying Huang; Liying Wang; Wei Liu; Haiqu Song; Mingzhu Lin; Xiulin Shi; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

Review 3.  Efficacy of Continuous Glucose Monitoring on Glycaemic Control in Pregnant Women with Gestational Diabetes Mellitus-A Systematic Review.

Authors:  Agata Majewska; Paweł Jan Stanirowski; Mirosław Wielgoś; Dorota Bomba-Opoń
Journal:  J Clin Med       Date:  2022-05-23       Impact factor: 4.964

4.  The impact of Ramadan fasting on glucose variability in type 2 diabetes mellitus patients on oral anti diabetic agents.

Authors:  Dante S Harbuwono; Farid Kurniawan; Nani C Sudarsono; Dicky L Tahapary
Journal:  PLoS One       Date:  2020-06-29       Impact factor: 3.240

Review 5.  The Role of Dietary Carbohydrates in Gestational Diabetes.

Authors:  Vikkie A Mustad; Dieu T T Huynh; José M López-Pedrosa; Cristina Campoy; Ricardo Rueda
Journal:  Nutrients       Date:  2020-01-31       Impact factor: 5.717

Review 6.  Sudden death in epilepsy: There is room for intracranial pressure.

Authors:  Maxine Dibué; Jochem K H Spoor; Marjolein Dremmen; Christiane Freiin von Saß; Daniel Hänggi; Hans-Jakob Steiger; Philippe Ryvlin; Marcel A Kamp
Journal:  Brain Behav       Date:  2020-09-19       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.